← Shaanxi Kanghui Pharm overview

Shaanxi Kanghui Pharm vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shaanxi Kanghui Pharm Co Ltd (603139.CG)

Q3 2026
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

August 2026
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Latest
▲2▼2

Kanghui pivots to AI computing power with huge contracts, but debt and weak core pharma weigh

  • New AI computing power contracts worth up to 2.4 billion yuan Kanghui's subsidiary signed two computing power service contracts: one worth 415-679 million yuan in July and another worth 1.72 billion yuan in September. These deals show real demand for its new AI computing business, which could bring in steady revenue over five years and help offset weak traditional medicine sales.

    These large contracts are the main new growth driver and explain why the stock has nearly doubled this year.

  • Debt to fund 1.14 billion yuan server purchase To fulfill the big computing contract, Kanghui must buy 1.14 billion yuan of servers, mostly with borrowed money. This will push its debt ratio from 69% to about 78%, increasing financial risk. The company also said the deal's impact on 2026 profit is uncertain, so the market may worry about the cost of this expansion.

    This is the main counterweight: the growth comes with significantly higher debt and uncertain near-term profit.

  • First-half profit turns positive, but only thanks to asset sales Kanghui reported a net profit of 9.09 million yuan for the first half, reversing a loss. However, the profit came mainly from selling idle assets, while the core business still lost money on an adjusted basis. Revenue also fell 17%. This shows the underlying medicine business remains weak.

    The profit turnaround is a headline positive, but the reliance on one-off gains and falling revenue is a real concern for future earnings.

  • Divesting troubled subsidiary Chunsheng Pharmaceutical Kanghui is selling its 51% stake in Chunsheng Pharmaceutical for 64 million yuan, after the unit repeatedly missed profit targets and the original owners couldn't pay compensation. The sale price is only 12.7% above the original investment, so it's a loss-making exit. This removes a drag but also signals past acquisition troubles.

    This divestiture is a negative event that highlights management challenges and past poor performance, affecting investor confidence.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.